IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Serum Mannan-Binding Lectin in Egyptian Patients With Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment

AUTHORS

Serag Esmat 1 , * , Dalia Omran 2 , Gihan A. Sleem 2 , Laila Rashed 2

AUTHORS INFORMATION

1 Department of Internal Medicine, Faculty of Medicine, Cairo University, seragesmat@hotmail.com, Egypt

2 Department of Tropical Medicine, Faculty of Medicine, Cairo University, Egypt

How to Cite: Esmat S, Omran D, Sleem G, Rashed L. Serum Mannan-Binding Lectin in Egyptian Patients With Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment, Hepat Mon. Online ahead of Print ; 12(4):259-264. doi: 10.5812/hepatmon.704.

ARTICLE INFORMATION

Hepatitis Monthly: 12 (4); 259-264
Article Type: Research Article
Received: April 13, 2011
Accepted: May 10, 2011
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Chronic hepatitis C virus (HCV) infection is a major worldwide public health problem. Egypt has the highest prevalence of adult HCV infection in the world, averaging 15%–25% in rural communities. Mannan-binding lectin (MBL) is a liver-derived pluripotent serum lectin that plays a role in the innate immune system of the host. It is an acute-phase protein that is involved in the activation of the classical complement pathway. MBL may play a defensive role in HCV infection.
Objectives: To investigate the relationship between MBL concentration and HCV infection in Egyptian patients suffering chronic hepatitis C.
Patients and Methods: Serum samples obtained from 35 Egyptian hepatitis C patients and 30 normal controls were assayed for MBL. MBL concentrations were correlated to disease characteristics and treatment response.
Results: Serum MBL was significantly higher in HCV patients than in controls, but no relationship was found between MBL concentration and disease progression in terms of hepatic fibrosis and inflammation. Responders to interferon (INF)-based therapy had significantly higher serum MBL than non-responders.
Conclusions: We found no association between serum MBL concentration and progression of HCV related liver disease. Responders to INF-based therapy had significantly higher serum MBL than non-responders.


  • Implication for health policy/practice/research/medical education:
    MBL may be considered as a predictor of response to antiviral therapy in HCV patients and MBL replacement therapy may improve the response to antiviral therapy in these patients.
  • Please cite this paper as:
    Esmat S, Omran D, Sleem GA, Rashed L. Serum Mannan-Binding Lectin in Egyptian Patients With Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment. Hepat Mon. 2012;12(4):259-64. DOI: 10.5812/hepatmon.704

Copyright © 2012 Kowsar Corp. All rights reserved.


Keywords

Hepatitis C Interferon Mannan Egypt

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: